Domainex Appoints Dr Bodo Spori as Head of Business Development for Europe
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe. His appointment reflects Domainex’s commitment to offering cutting-edge, integrated drug discovery services to an increasing number of customers across Europe, and supporting the discovery of innovative new therapeutic candidates to treat unmet human diseases.
Bodo Spori is a German neuroscientist, born and raised in Belgium, with more than 13 years of experience in strategic business development roles. He joins Domainex from Cyprotex, a subsidiary of Evotec AG, where he oversaw European and global sales initiatives in his role as VP of Business Development. Previously, he worked as the Senior European Business Development lead at Scottish Biomedical Ltd.
“Domainex has an excellent reputation for delivering high quality drug discovery services to a global client base,” said Dr Spori. “Meeting Domainex’s management team and scientists clearly illustrated their expertise and collaborative approach, which underpins the 'every compound counts' philosophy driving their growth. I also sensed the strong commitment to innovation that has led to both the development of Domainex’s proprietary platforms, such as Combinatorial Domain Hunting, as well as several candidate drugs. I am delighted to be joining at such a dynamic and exciting time in the company’s development, and look forward to bringing my own experience to help further advance the business.”
“I am delighted to welcome Bodo to Domainex,” commented Dr Tom Mander, COO of the company. “His successful track record of identifying and forging strategic client collaborations, coupled with his experience of working in the fields of assay development, protein production, in vitro and in vivo pharmacology, compound profiling, screening and ADME, make him the ideal addition to our business development team. Bodo will play a strategic role, building on our relationships with pharmaceutical and biotechnology companies across Europe and, via our services and expertise, help them advance their programmes towards development."
This article has been republished from materials provided by Domainex Ltd. Note: material may have been edited for length and content. For further information, please contact the cited source.
T Cells Attack and Kill Dopamine-Producing Cells in Parkinson's diseaseNews
Researchers in Germany discover a potential new target for treating Parkinson's diseaseREAD MORE
Kidney Cancer Driver Could Lead to New Treatment StrategyNews
Scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.READ MORE
Targeting Headaches and Tumors with Nano-SubmarinesNews
Scientists have developed a new method to enable miniature drug-filled nanocarriers to dock on to immune cells, which in turn attack tumors. In the future, this may lead to targeted treatment that can largely eliminate damage to healthy tissue.READ MORE